Table 5.

Factors associated with HABP/VABP in high-risk patients, adjusted odds ratio^* (95% confidence interval)

	Age Group
Factor	Overall	120 days to 18 years	<120 days	<28 days
Age	1.22 (1.08, 1.37) †	1.17 (1.03, 1.34)†	1.02 (0.99, 1.04) ‡	0.81 (0.66, 1.01)‡
Height, cm	0.97 (0.96, 0.99)	0.98 (0.96, 1.00)
Weight, kg			0.45 (0.26, 0.79)	0.43 (0.21, 0.87)
ICU length of stay, days	1.01 (1.00, 1.02)	1.01 (1.00, 1.01)	1.02 (0.99, 1.04)	1.07 (0.99, 1.15)
Aspiration risk	3.81 (2.17, 6.68)	4.39 (2.34, 8.23)
Noninvasive ventilation	0.55 (0.32, 0.93)	0.53 (0.28, 0.99)	0.41 (0.14, 1.21)	0.31 (0.07, 1.32)
Vasopressor/inotropic therapy	0.67 (0.39, 1.13)		0.38 (0.11, 1.31)
Corticosteroid use at current hospitalization	1.74 (0.87, 3.46)
Proton pump or H2-blocker therapy	0.37 (0.22, 0.64)	0.46 (0.25, 0.84)	0.24 (0.07, 0.85)
Blood product transfusion in prior 7 days	1.82 (1.02, 3.24)		2.96 (0.91, 9.66)
Frequent suctioning	3.64 (2.17, 6.12)	3.47 (1.90, 6.35)	7.32 (2.10, 25.47)	5.71 (1.32, 24.7)
Invasive monitoring				0.17 (0.01, 2.05)

^*Stepwise multivariable logistic regression beginning with the variables: age; sex; height; weight; hospital admission type (emergent surgical, elective surgical or non-operative); admission source; hospital length of stay at screening; ICU length of stay at screening; primary ICU admission diagnosis; aspiration risk; medical comorbidities; type of ventilation; duration of ventilation; receipt of enteral nutrition; inotropic therapy; chemotherapy during current admission; biologic agents during current admission; corticosteroids during current admission; acid suppression therapy; blood product transfusion in the last 7 days; systemic antibiotics within the last 90 days; frequent oral, nasotracheal or tracheal suctioning; massive volume resuscitation; and invasive monitoring. Each factor is adjusted for all other factors;

^†years,

^‡days